BioPharm Intl

Talking biopharmaceuticals, biotechnology, bioprocessing and related pharma manufacturing.

[BioPharm Intl @BioPharmIntl]

Our latest survey of #biopharma professionals on #DigitalTransformation in the industry uncovered a hype-actual adoption gap.

Get the full industry report at https://t.co/xZJqIJbLID

#AI

[BioPharm Intl @BioPharmIntl]

@FDACBER’s draft guidance on gene therapy and genome editing may transform CMC and data strategies for biopharma. How is your team preparing for these regulatory changes? Learn more: https://t.co/RyEtO2QB75

#GeneTherapy #CGT #RegulatoryAffairs

[BioPharm Intl @BioPharmIntl]

Switzerland Innovation Park Main Campus is advancing biopharma with integrated biomedical engineering and 3D-printed solutions. Explore Dr. Johannes Eisenhut’s insights on global R&D impact: https://t.co/PljaGup7hG

#BiopharmaInnovation #RegenerativeMedicine #3DPrinting

[BioPharm Intl @BioPharmIntl]

@bmsnews with Biokin's SystImmune report promising interim phase 3 results for the EGFRxHER3 bispecific ADC, iza-bren, which met OS and PFS endpoints in TNBC and ESCC phase 3 trials. How does this impact oncology care? Learn more: https://t.co/dNUnir2aI0

#CancerTrials #Oncology

[BioPharm Intl @BioPharmIntl]

Integrated drug development models are helping biopharma teams reduce tech-transfer risk, eliminate delays, and accelerate complex biologics from discovery to clinic. #Biologics
https://t.co/qIGUnaOLTG

[BioPharm Intl @BioPharmIntl]

Dual PD-L1/VEGF-A blockade with pumitamig plus chemo shows high response and 100% disease control in advanced NSCLC. Could this set a new standard? Learn more: https://t.co/cHiRi1aycj

@BioNTech_Group @bmsnews
#NSCLC #ImmunoOncology

[BioPharm Intl @BioPharmIntl]

Fosun Pharma and @tevapharm have dosed the first patient in China with FXB0871, a novel PD-1 targeted IL-2 fusion protein. Could this advance the future of combination immunotherapy? Learn more: https://t.co/Td628NDPu1

#ImmunoOncology #CancerResearch #BiotechNews

[BioPharm Intl @BioPharmIntl]

Successful tech transfer starts with alignment, risk management, and process precision—Rentschler BioPharma’s dual-site model helps accelerate timelines while ensuring quality and manufacturing flexibility. #Biomanufacturing
https://t.co/6rmKT0BM3I

[BioPharm Intl @BioPharmIntl]

Strategic investments in manufacturing and supply chains are unlocking faster, more reliable, and higher-quality delivery—while enabling global agility at scale. #OperationalExcellence
https://t.co/2XFt2ojK7f
https://t.co/5zjDLrMiXX

[BioPharm Intl @BioPharmIntl]

@biohub has unveiled an open-source AI model to advance protein design for cancer and immune therapies. Will this reshape biopharma R&D? Explore the impact: https://t.co/V88IZeJlPf

#AIDrugDiscovery #ProteinDesign #Bioinformatics

[BioPharm Intl @BioPharmIntl]

@swissinnova Basel’s life sciences hub is transforming as global leaders and startups drive innovation across the biopharma value chain. Discover insights from SENN Development's Dr. Johannes Eisenhut: https://t.co/MrEimXliVM

#LifeSciences #BiotechEcosystem #Innovation

[BioPharm Intl @BioPharmIntl]

Unlock complete analytical workflows for GLP-1 therapeutics—ensuring purity, stability, and compliance across development and QC: https://t.co/nefjELWvkd #Biopharma

[BioPharm Intl @BioPharmIntl]

Olezarsen (Tryngolza; Sobi and @ionispharma)
cut triglycerides by 66% and acute pancreatitis risk by 85% in severe hypertriglyceridemia. What could this mean for future payer decisions? Learn more: https://t.co/GmSI449APv

#hypertriglyceridemia #RNAtherapy #pancreatitis

[BioPharm Intl @BioPharmIntl]

Scalable, modular manufacturing and AI-driven automation are transforming CGT production, according to @CRiverLabs' Dr. Alan Smith. How is your team integrating flexibility and AI in CGT manufacturing? Learn more: https://t.co/zbH6axV9IX

#CellAndGeneTherapy #Biomanufacturing

[BioPharm Intl @BioPharmIntl]

Can 3D neural microtissues redefine cell therapy for Parkinson’s? @treefrogtx unveils new preclinical data on TFG-001’s dopamine release and reinnervation. Learn more: https://t.co/nO6N0aSY9r

#Parkinsons #CellTherapy #RegenerativeMedicine

[BioPharm Intl @BioPharmIntl]

Real-time patient insights. Scalable engagement. Smarter biopharma connections from discovery through commercialization.

Learn more: https://t.co/wCX9i15IGm

#Biopharma

[BioPharm Intl @BioPharmIntl]

Designing safe cleaning validation for highly potent ADCs? Paul Lopolito of #STERIS highlights the importance of HBELs, degradation data, and risk-based strategies. Explore his insights: https://t.co/rpmyCPYwRe

#ADC #CleaningValidation #Biopharma

[BioPharm Intl @BioPharmIntl]

@BioMarin's vosoritide shows significant growth gains in children with hypochondroplasia in the Phase 3 CANOPY-HCH-3 study. Could this reshape care for FGFR3-related skeletal dysplasia? Read more: https://t.co/gqxlaaRlYi

#Hypochondroplasia #RareDiseaseResearch

[BioPharm Intl @BioPharmIntl]

@AvaiBio and @AustrianovaST mark a major milestone in α-Klotho cell therapy with a GMP master cell bank for Cell-in-a-Box. Next: viral testing. How do you track early CMC progress? Read more: https://t.co/dlttd0uUYm

#CellTherapy #GeneTherapy #HealthyAging

[BioPharm Intl @BioPharmIntl]

inSPECt™ MS is advancing HCP profiling with native digestion and LC-MS analysis—delivering sensitive, low-ppm quantification to support safer, more effective biopharmaceuticals. #Bioprocessing
https://t.co/BojLk9ye9u

[BioPharm Intl @BioPharmIntl]

@CellularOrigins CEO Dr. Edwin Stone discusses how automation is driving scalable solutions in CGT to free developers from scaling worries. Watch the full interview: https://t.co/79yn9BzlVB

#CellTherapy #GeneTherapy #Biomanufacturing #ASGCT2026